No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients

Clin Investig. 1993 Aug;71(8):610-2. doi: 10.1007/BF00184484.

Abstract

Carnitine is an essential factor for the transport of long-chain fatty acids and is important for the heart muscle. A longitudinal study in type 2 diabetic patients was carried out. Carnitine levels were observed before and during metabolic intervention with dietary measures and either sulfonylurea or insulin treatment. In both treatment groups a significant glycemic improvement was observed after 3 months (insulin treatment group: hemoglobin A1c 11.3 +/- 2.8 versus 7.0 +/- 1.0; sulfonylurea treatment group; hemoglobin A1c 11.3 +/- 1.4 versus 7.3 +/- 0.9). Carnitine levels did not differ from a control group and did not change significantly during the observed period.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Blood Glucose / metabolism*
  • Carnitine / blood*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Humans
  • Insulin / therapeutic use*
  • Longitudinal Studies
  • Male
  • Middle Aged

Substances

  • Blood Glucose
  • Insulin
  • Carnitine